Modacin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Modacin

What is Modacin? (Ceftazidime)

Property Description
Active ingredient Ceftazidime
Form Sterile powder for injection
Pharmacological class beta-Lactam / Third-Generation Cephalosporin Antibiotic
General purpose Management of severe systemic bacterial infections
Origin Semi-synthetic

What Type of Medicine is Modacin?

Modacin is a prescription-only medication defined by its active component, the semi-synthetic antibiotic Ceftazidime. It is structurally classified as a beta-Lactam antibiotic and belongs to the third-generation cephalosporin family. This advanced classification is clinically recognized for providing a broad spectrum of activity against many gram-negative bacteria, which sets it apart from older cephalosporins. This classification reflects its specialized utility in treating complex, resistant infections.

Composition and Delivery Form

Ceftazidime is typically manufactured as a sterile powder for injection, representing a single-ingredient product housed in sealed vials. This formulation requires reconstitution with an aqueous solvent, such as sterile water or saline solution, immediately prior to use. The administration of Modacin is always parenteral, meaning it must be delivered directly into the patient's system via an intravenous (IV) solution or an intramuscular (IM) solution. This specialized injection route is necessary to achieve high and reliable concentrations of the medicine in the body, a requirement for effectively fighting severe systemic infections.

General Purpose of this Bactericidal Agent

Ceftazidime functions as a potent bactericidal agent that directly kills susceptible pathogenic organisms. The core purpose of Modacin is the decisive elimination of these organisms to resolve severe systemic bacterial infections. Its mechanism involves irreversibly inhibiting the bacteria's ability to synthesize their protective cell wall, a crucial function for survival. This targeted action makes the compound critically effective, for example, in managing deep-seated respiratory or complicated intra-abdominal infections. The compound is highly valued within the medical community for its specific activity against Pseudomonas aeruginosa, an opportunistic pathogen frequently implicated in hospital-acquired infections.

Regulatory References

  1. Ceftazidime Injection: MedlinePlus Drug Information

What side effects are possible with Modacin?

Possible Side Effects and Safety Information

The safety profile of Modacin (Ceftazidime) is documented through regulatory classifications, grouping potential adverse reactions by their physiological system and frequency of occurrence. These classifications are defined in official government documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Reactions classified as common in official labeling, potentially affecting up to 1 in 10 people, include diarrhea, rash, eosinophilia, thrombocytosis, and inflammation or pain at the injection site (phlebitis). Uncommon effects may involve fungal infections (e.g., oral thrush), headache, dizziness, abdominal pain, nausea, and temporary changes in white blood cell or platelet counts.

Regulatory documents highlight several serious adverse reactions. These include severe, immediate allergic reactions (anaphylaxis) and Clostridioides difficile-associated diarrhea (CDAD), which may occur during or subsequent to treatment. The label also notes the risk of serious neurological events, such as seizures, myoclonus, and encephalopathy.

Specific safety considerations apply to patients with renal impairment (reduced kidney function). Dosage adjustments are necessary in this population, as failure to do so can increase the risk of neurological sequelae. Furthermore, the medicine is contraindicated in individuals with a known severe immediate hypersensitivity history to cephalosporins or other beta-lactam antibiotics. The medicine may also cause a positive Coombs’ test, which can interfere with certain laboratory blood tests.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory documentation for Modacin (Ceftazidime) overdose defines the primary concern as Central Nervous System (CNS) toxicity, which manifests due to elevated systemic drug concentrations. Officially documented overdose presentations include severe neurological sequelae such as encephalopathy, involuntary muscle movements (myoclonus), and convulsions (seizures). The most severe outcomes are classified by regulators as life-threatening or fatal neurological adverse reactions, including the progression to coma.

A specific risk factor is explicitly detailed: overdose symptoms are most frequent in patients with renal impairment when the dosage is not appropriately adjusted, as the drug's clearance relies heavily on the renal system.

Regulators mandate that individuals seek immediate emergency medical attention or contact a Poison Control Center for any suspected overdose event. Treatment is officially defined as symptomatic and supportive. It is stated that no specific antidote is known. However, regulatory guidance confirms that procedures such as haemodialysis or peritoneal dialysis may be used to effectively reduce elevated drug concentrations in the body.

Therapeutic Uses of Modacin

What Modacin Treats: Main Uses and Benefits

Modacin (Ceftazidime) is commonly used to treat severe, systemic infections caused by bacteria, helping to address challenging symptoms that interfere with daily functioning and create noticeable physiological strain. The medication is applied across therapeutic domains involving heightened systemic burden.

It is considered relevant for easing symptoms associated with life-threatening conditions such as septicemia (blood infection), bacterial meningitis, and severe infections of the lungs (pneumonia), abdomen, bones, joints, and urinary tract. Modacin is commonly used to help with managing symptoms in situations where the patient is vulnerable, particularly when the infection is caused by highly resistant bacteria.

The medicine is often used during phases when symptoms become more noticeable, particularly in situations involving multidrug-resistant Gram-negative bacteria, such as Pseudomonas aeruginosa. When applied appropriately, it may assist with managing symptoms in these complex situations, supporting general well-being during symptomatic phases.


Quick Fact: Relief for Systemic Symptoms Modacin is commonly used to help with symptoms related to systemic imbalance, such as persistent fever and chills, which are often the distressing manifestations of widespread bacterial infections. It supports the patient during difficult episodes by easing the overall symptom load.

Regulatory References

  1. NIH MedlinePlus overview of Ceftazidime

Eligibility and Restrictions for Use

Who Can and Cannot Use Modacin?

The eligibility for Modacin (Ceftazidime) is strictly defined by regulatory documents, focusing on patient history and physiological status.


Absolute Contraindications

Use of Modacin is strictly prohibited (contraindicated) for individuals with a known history of immediate hypersensitivity or serious allergic reactions to Ceftazidime itself. This prohibition also extends to patients with a history of severe allergic reactions to any antibiotic in the cephalosporin class or the penicillin and other beta-lactam antibiotic classes.


Condition-Based and Age-Related Limitations

Eligibility is established for adults and pediatric patients two months of age and older. However, special regulatory considerations apply to several populations:

  • Renal Function: Patients with impaired kidney function require conditional use. Regulatory guidelines mandate that the dose be adjusted to prevent the accumulation of the medicine.
  • Older Adults: For patients over 80 years of age, the total daily dose should not normally exceed 3 grams due to reduced clearance.
  • Pregnancy and Lactation: Use during pregnancy is restricted to circumstances where the clinical benefit clearly outweighs the potential risk. Use during breastfeeding is generally deemed acceptable.
  • Neonates: The safety and efficacy of continuous infusion of Modacin has not been established for infants younger than two months old.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents establish Modacin's interaction profile based on three primary types of constraints: formal prohibitions, pharmacodynamic risk enhancement, and clearance-related accumulation.

Category Interacting Substance(s) Official Interaction Outcome / Description
Formal Contraindication Live Bacterial Vaccines (e.g., BCG, Cholera, Typhoid) Co-administration is contraindicated due to documented pharmacodynamic antagonism.
Toxicity Enhancement Aminoglycosides and other Nephrotoxic Agents Concomitant use is officially associated with an increased potential for nephrotoxicity and ototoxicity (additive risk).
Pharmacodynamic Antagonism Chloramphenicol The FDA label notes an antagonistic effect observed in vitro with this combination.

Clearance and Exposure-Related Notes

Modacin is primarily eliminated by the kidneys, and its official interaction profile reflects this. The administration of Probenecid may increase the serum concentration of Modacin by competing for renal tubular clearance. However, no mandatory timing separation rules are documented in the prescribing information for this or other agents.

Population-Specific and Procedural Constraints

The risk of neurological adverse reactions is officially increased in patients with renal impairment due to the resultant elevated serum concentrations and accumulation of Modacin. Concomitant use with nephrotoxic agents may exacerbate this population-specific risk. Additionally, the drug may cause a false-positive reaction for glucose in the urine when tested using non-enzymatic methods (such as CLINITEST tablets), requiring the use of enzymatic glucose oxidase reactions instead.

Mechanism of Action

Primary Modulation of the [Specific Receptor/Enzyme] System

Modacin’s core mechanistic activity centers on its highly selective binding to the [Specific Receptor or Enzyme Type]. This initial, specific interaction acts to either initiate or suppress signaling events, resulting in the adjustment of activity within biological systems where specific transmitters or mediators dominate the physiological process.


Modulation of Heightened Signal Transduction Cascades

The drug’s influence extends beyond the initial binding site by operating within well-characterized molecular cascades. Modacin modifies early molecular steps to alter signaling dynamics, thus modifying the propagation velocity or amplitude of mediator activity through pathways relevant in states of heightened physiological activation.


Influence on Core Regulatory Systems

-The cumulative effect of Modacin’s targeted pathway interference is its influence on core regulatory systems. The mechanism results in altered activity within these central and/or peripheral pathways and modulates the signaling intensity of overactive or dysregulated physiological processes. This action constitutes the final step in the drug’s established pharmacodynamic pathway.

Dosage and Administration Information

How Modacin (Ceftazidime) is Used

Modacin (Ceftazidime) is an antibiotic prescribed for use only via a parenteral route, meaning it is delivered directly into the patient's system as an injection or infusion. The two official methods of administration are intravenous (IV) injection or infusion and deep intramuscular (IM) injection.

Administration and Preparation Requirements

The medication is supplied as a sterile powder for injection and requires mandatory steps prior to use. The powder must be reconstituted and often further diluted with specified, compatible solvents, such as sterile water or sodium chloride injection, immediately before administration. For IV use, the solution may be administered as a slow injection over three to five minutes or as an intermittent infusion over 20 to 30 minutes. The solution should not be mixed with certain other agents in the same container.

Official Dosing and Frequency

Dosing for Modacin follows a divided daily schedule to ensure continuous therapeutic exposure. The standard adult dosage range is typically 1 gram to 2 grams per dose, administered every 8 to 12 hours. For severe infections, the dose may be increased up to 2 grams every 8 hours.

Population Group Labeled Dosing Guideline
Standard Adult Dose 1 g to 2 g every 8 to 12 hours
Renal Impairment Dose and interval must be adjusted downward based on creatinine clearance
Pediatric Patients Weight-based dosing (e.g., 30–50 mg/kg every 8 hours) for infants and children

A critical procedural rule requires that the dose and interval be formally adjusted for patients with documented renal impairment to prevent accumulation. If a dose is missed, it should be taken as soon as possible, but if it is near the time for the next dose, the missed dose should be skipped to avoid dose doubling.

Recent Clinical Evidence

The research record for Modacin (Ceftazidime) is based on a structured history of clinical evaluation, including numerous randomized controlled trials (RCTs) and comprehensive literature reviews. This record has been evaluated by regulators and describes the context in which the medicine was studied for severe systemic infections. The evidence helps contextualize what has been observed so far, but research does not determine whether an individual will respond similarly.


Evidence for Core Indications and Special Populations

The evidence base for Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI) includes short-term Phase III RCTs. These trials compared a Modacin-based regimen against other broad-spectrum antibiotics, studying clinical response (e.g., resolution of fever) and microbiological eradication at a required Test-of-Cure visit. Modacin was also evaluated in comparative trials for febrile neutropenia (fever in immunosuppressed patients), where research monitored outcomes related to systemic imbalance, such as the time it took for fever to resolve and the need for the initial treatment plan to be changed.

Research explored how the drug is processed in pediatric patients through pharmacokinetic (PK/PD) studies, confirming that drug concentrations appear to align with those observed in adults. Separately, research is important for describing the drug’s handling by the body in patients with reduced kidney function.

Documented Research Gaps and Uncertainties

The research record highlights several limitations. Due to the emergence of resistant bacteria, the most recent high-quality RCTs often examine Modacin only when combined with another agent, meaning comparative evidence is lacking for the use of Modacin alone against some resistant organisms. Furthermore, many key trials for febrile neutropenia are older, meaning evidence quality varies and must be considered against current resistance patterns. Additionally, because most trials focused on short-term success, long-term effects are not fully established regarding the sustained measurement of infection recurrence beyond the Test-of-Cure visit.

Key Studies & References

  1. Ceftazidime Drug Information and Regulatory Overview
  2. Clinical Review of Ceftazidime Efficacy in Complicated Intra-Abdominal and Urinary Tract Infections
  3. Ceftazidime Use in Cystic Fibrosis Patients with Pseudomonas aeruginosa Exacerbations (Clinical Studies)
  4. Pharmacokinetic/Pharmacodynamic (PK/PD) Data for Ceftazidime in Pediatric and Renal Impairment
  5. Evidence Review of Ceftazidime Monotherapy in Febrile Neutropenia

Frequently Asked Questions (FAQ)

Common questions about Modacin (FAQ)


Q: How quickly can I expect to see an effect from Modacin?

Official prescribing information describes how the medicine is processed in the body. Peak levels of Modacin in the bloodstream are generally reached rapidly after injection, typically within minutes to one hour. The time it takes for visible signs of the infection to begin changing is part of the clinical observation process conducted by a healthcare provider.


Q: Does Modacin lose effectiveness over time?

Regulatory documents note that, as with other antibacterial drugs, bacteria may develop resistance during the course of treatment with Modacin. This development of resistance is noted as a possibility that could potentially lead to clinical failure. Official guidance emphasizes that Modacin should only be administered as prescribed.


Q: Does Modacin interact with oral contraceptives?

Official information indicates that certain types of antibiotics, like Modacin, may reduce the effectiveness of medications that contain estrogen. This includes some oral contraceptive products. The information indicates this concern should be discussed with the prescribing healthcare professional.


Q: Will Modacin affect my sleep schedule?

Official regulatory labeling for Modacin does not specifically list effects on sleep, such as insomnia. However, the product information does include warnings about the potential for severe, though uncommon, neurological reactions. These reactions, such as seizures or encephalopathy, have been reported in the medical literature, particularly when the medicine accumulates in patients with reduced kidney function.


Q: What happens if I forget to take Modacin one day?

The official dosing guidance for Modacin is based on a structured schedule (every 8 to 12 hours) to ensure that the necessary concentration of the medicine is maintained in the body. If an entire day of doses is missed, the prescribing healthcare provider should be consulted immediately. This consultation is necessary to ensure the proper schedule is resumed and continuous therapeutic exposure is maintained.


Q: Why is Modacin prescribed for more than one condition?

Modacin is an antibacterial agent approved for a variety of severe systemic bacterial infections caused by organisms that are known to be susceptible to the drug. These approved uses, listed in the regulatory documents, include infections affecting the lower respiratory tract, skin and skin structure, urinary tract, and certain intra-abdominal infections.


Q: Are the side effects of Modacin usually temporary?

Regulatory documentation notes that some temporary changes in laboratory test values, such as minor elevations in liver enzymes, were observed in clinical studies and resolved during the study period. However, serious adverse reactions may occur during or after treatment, including conditions like C. difficile-associated diarrhea.


Q: What is the purpose of the black box warning (if any) on Modacin?

The official labeling for Modacin (Ceftazidime alone) does not contain a 'Black Box Warning,' which is the most serious safety warning from the FDA. However, the product does contain important warnings about the risk of severe hypersensitivity (allergic) reactions and the potential for C. difficile-associated diarrhea.


Q: Can Modacin be taken long-term, according to official guidelines?

The official prescribing information indicates that Modacin is generally used for a short course of treatment, often continuing for at least two days after the signs of infection have resolved. For certain complicated infections, the duration of therapy is determined by the healthcare provider.


Q: Is it normal to feel a change in appetite after starting Modacin?

Regulatory documentation lists a loss of appetite as a rare side effect that has been reported.


Q: Does Modacin cause any known changes to skin sensitivity?

Official product information notes the potential for skin reactions, such as developing a rash. However, regulatory documents do not list general changes to skin sensitivity, like increased sensitivity to sun exposure (photosensitivity).


Q: What are the general expectations about the duration of its effect after a dose?

Pharmacokinetic studies show that Modacin has a half-life of approximately two hours in people with normal kidney function. Dosing is scheduled every 8 to 12 hours specifically to maintain the concentration of the drug required to combat the severe infection effectively between administrations.


Q: What are the research findings regarding Modacin's use in different age groups?

Research has been conducted on Modacin's processing in pediatric patients to ensure drug concentrations are comparable to those in adults. Additionally, official guidelines specify a reduced maximum daily dose for older adults, particularly those over 80 years of age, due to naturally reduced kidney clearance.


Q: Is Modacin a controlled substance?

Official drug classifications confirm that Modacin (Ceftazidime) is a prescription-only medication. It is not listed as a controlled substance by regulatory agencies in the United States.

How should Modacin be stored and disposed of?

How to Store and Dispose of Modacin?

Modacin (Ceftazidime sterile powder for injection) requires specific storage and disposal protocols as defined by regulatory labeling.

Storage Conditions

Requirement Constraint
Temperature Must be stored at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection The vial must be kept in the outer carton to protect the medicine from light.
Safety It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Instructions

Any unused or expired product must be discarded in accordance with local, national, and international regulatory requirements for pharmaceutical waste. Disposal must ensure the product is not released into wastewater or the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Modacin found in:

A-Z Index: